LUMITHERA INC
Poulsbo, WA · Founded 2013 · CIK 0001615388 · Medtech · Acquired
Multi-wavelength LED light delivery system (LT-300) for photobiomodulation therapy in ophthalmology
lumithera.com →- Grants
- $8.8M
- 11 awards
- Sector median: 1
- Raised
- $6.7M
- 9 Form D · May 2024
- 29 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 20
- 6 granted · 14 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201420162018202020222024
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $325,000 | |
| Federal grant | Department of Health and Human Services · Phase I · The Development of Photobiomodulation for the Treatment of Dry Age-related Macular Degeneration | $267,223 | |
| Federal grant | Department of Health and Human Services · Phase I · A pilot clinical study to evaluate the use of photobiomodulation in patients with dry age-related macular degeneration | $256,010 | |
| Private capital raised | Form D · SEC | $5,000,000 | |
| Federal grant | Department of Health and Human Services · Phase I · A pilot clinical study to evaluate the use of photobiomodulation in patients with dry age-related macular degeneration | $140,000 | |
| Federal grant | Department of Health and Human Services · Phase I · The Development of Photobiomodulation for the Treatment of Dry Age-related Macular Degeneration | $89,685 | |
| Private capital raised | Form D · SEC | $775,000 | |
| Private capital raised | Form D · SEC | $665,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Clinical Evaluation of Photobiomodulation (PBM) in dry AMD Patients | $1,502,600 | |
| Federal grant | Department of Health and Human Services · Phase II · Clinical Evaluation of Photobiomodulation (PBM) in dry AMD Patients | $2,528,200 | |
| Private capital raised | Form D · SEC | $100,000 | |
| Private capital raised | Form D · SEC | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Clinical Evaluation of Photobiomodulation (PBM) in dry AMD Patients | $1,025,600 | |
| Federal grant | Department of Health and Human Services · Phase II · The Use of Photobiomodulation (PBM) in the Treatment for Diabetic Macular Edema | $897,302 | |
| Private capital raised | Form D · SEC | $615,000 | |
| Federal grant | Department of Health and Human Services · Phase II · The Use of Photobiomodulation (PBM) in the Treatment for Diabetic Macular Edema | $674,742 | |
| Federal grant | Department of Health and Human Services · Phase II · The Use of Photobiomodulation (PBM) in the Treatment for Diabetic Macular Edema | $239,680 | |
| Private capital raised | Form D · SEC | $819,975 | |
| Federal grant | Department of Health and Human Services · Phase II · LIGHTSITE IIIB: Clinical Evaluation of Photobiomodulation (PBM) in dry AMD Patients | $1,169,339 | |
| Private capital raised | Form D · SEC | $2,427,638 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1759 | AMG DETECTION, INC. | — | — |
| 1760 | EVOLUTION DEVICES, INC. | — | — |
| 1761 | E25Bio Inc. | — | $6.8M |
| 1762 | LUMITHERA INC | — | $6.7M |
| 1763 | Bruin Biometrics, LLC | — | — |
| 1764 | WICKED SHEETS, LLC | — | $1.4M |
| 1765 | IHNNOVA LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Daniel BertholetDirector
- Scott BradleyExecutive Officer
- Shupeng CaoDirector
- Todd ChristieDirector
- Cindy CroissantExecutive Officer
- Robert DotsonDirector
- Joseph FontanettaDirector
- Graham MerryDirector
- Ryan MontecuccoExecutive Officer
- Duane MorrisonExecutive Officer
- Tracy PuckettExecutive Officer
- Jackson StreeterDirector
- Art TaylorDirector
- ARTHUR TAYLORDirector
- Clark TedfordDirector · Executive Officer
- CLARK TEDFORDDirector · Executive Officer
- YIGANG YANGDirector
- Yang YigangDirector
Patents
- Multi-wavelength Phototherapy Devices, Systems, And Methods For The Non-invasive Treatment Of Damaged Or Diseased Tissueapplication
- Methods For Treating Ocular Diseaseapplication
- Methods For Treating Ocular Diseasegranted
- Methods, Apparatus, And Systems For Ophthalmic Testing And Measurementapplication
- Multi-wavelength Phototherapy Devices, Systems, And Methods For The Non-invasive Treatment Of Damaged Or Diseased Tissuegranted
- Methods, Apparatus, And Systems For Ophthalmic Testing And Measurementgranted
- Methods For Preventing And Treating Ocular Diseaseapplication
- Multi-wavelength Phototherapy Systems And Methods For The Treatment Of Damaged Or Diseased Tissuegranted
- Devices And Methods For Non-invasive Multi-wavelength Photobiomodulation For Ocular Treatmentsapplication
- Devices And Methods For Non-invasive Multi-wavelength Photobiomodulation For Ocular Treatmentsgranted
- Devices And Methods For Non-invasive Multi-wavelength Photobiomodulation For Ocular Treatmentsgranted
- Wearable Devices And Methods For Multi-wavelength Photobiomodulation For Ocular Treatmentsapplication
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.